Genomma Lab Internacional Sab De Cv Class B · BMV:LAB/B
Genomma Lab Internacional Sab De Cv Class B — Q3 2026 Earnings Presentation
27 slides from Genomma Lab Internacional Sab De Cv Class B's earnings presentation, Apr 1, 2026
Slide 1: Genomma Lab Q3 2026 Earnings Call
Genomma Lab.°® Internacional Genomma Lab Q3 2026 Earnings Call
Slide 2: Forward-looking statements disclaimer
This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limit
Slide 3: Recovery plan is reversing the trend, as anticipated
1 Recovery plan is reversing the trend, as anticipated: • Sell-in trend reversed: Mexico improving for a third straight quarter • Sell-out trend reversed: back to growth • Market share recovering: Suerox at a historic high at the leading retailer 2 EBITDA margin of 21% in line with expectations: • D
Slide 4: Mexico improves for a third straight quarter; sell-out turns positive
Mexico improves for a third straight quarter; sell-out turns positive Genomma Lab Mexico net sales annual growth Q1 2025 – Q3 2026 5.0% 3.0% Sell-out back to growth 0.0% -1.3% -2.4% -5.0% -4.4% -6.4% Stable or growing market -8.6% share -10.0% -15.0% Innovation accelerating growth -20.0% -22.1% -25.
Slide 5: Mexico sell-out follows the sell-in recovery path: back to growth
Mexico sell-out follows the sell-in recovery path: back to growth Monitored sell-out in units · YoY · quarters, with Q2–Q3 2026 opened by month +27 pp +24 pp +5.8% RECOVERY FROM Q2 2025 LOW TO SEP 2026 IMPROVEMENT APR → SEP 2026 Q3 2026 — BACK TO GROWTH Sell-out units — YoY growth México · monitored
Slide 6: Leading retailer sell-out is ahead of the curve: growth accelerating
Leading retailer sell-out is ahead of the curve: growth accelerating Monitored sell-out in units (pieces) · YoY · quarters, Q2–Q3 2026 opened by month +41 pp +29 pp +24.0% RECOVERY FROM Q2 2025 LOW TO SEP 2026 IMPROVEMENT APR → SEP 2026 Q3 2026 — GROWTH ACCELERATING Sell-out units — YoY growth Méxic
Slide 7: Sell-out and share accelerating at leading retailer since launch
Sell-out and share accelerating at leading retailer since launch Suerox at leading retailer: monthly sell-out growth vs. value market share 12.2% 12.6% Market share value, % 6.6% 8.1% 12.6% Value share in August: historic high (+6.0 pp vs. May) +81% Sell-out +38% growth YoY, units +81% Sell-out grow
Slide 8: Mexico unit sell-out improves in Q3
Mexico unit sell-out improves in Q3 OTC & PC growing above market; Suerox rebounds with innovation Genomma Mexico unit sell-out growth per category Q3 2026 vs. prior year Data in units Isotonic beverages rebounds in clients carrying innovation* +2.9% -9.7% ● +39.0% Jun–Aug 2026 ↳ +39.0% ● Average mo
Slide 9: Mexico improving sequentially; net income up 19% despite margin pressure
Mexico improving sequentially; net income up 19% despite margin pressure Q3 2026 Key financial metrics Year-over-year performance Mexico Net sales -2.4%, third consecutive sequential improvement; sell-out back to positive Flat SG&A despite increased opex & inflation Net profit +18.6% growth driven b
Slide 10: Working capital increase is temporary; underlying receivables +3 days
Q3 2026 WORKING CAPITAL Working capital increase is temporary; underlying receivables +3 days 1 TOTAL CASH CONVERSION CYCLE 2 RECEIVABLES ONLY Receivables + inventory − payables, days Receivable days Two temporary effects: +28 days (79%) +3 days Receivables excluding Argentina 165 ✓ Unchanged credit
Slide 11: Antonio Zamora, CFO
Slide 12: Financial Summary
FINANCIAL SUMMARY Q3 2026 % sales Million Mexican Pesos %A NETSALES $4,497.66 100% 1.3% GROSSPROFIT 2,7624 61.4% (2.6)% EBITDA 944.9 21.0% (10.3)% NET INCOME 514.9 11.4% 18.6% +168bps
Slide 13: Mexico
MEXICO Q3 NetRevenues (2.4)% ~{ EBITDA margin 20.0% aa pi
Slide 14: Exchange Rate USD | MXN
EXCHANGE RATE USD | MXN 19.5 19 -7.3% $18.63 18.5 Q3 25 18 17.5 $17.27 Q3 26 17 16.5 jul/2025 oct/2025 ene/2026 abr/2026 jul/2026 Average exchange rate for each period Source: Banxico
Slide 15: United States
UNITED STATES Q3 Net Revenues (30.5)% ee £ N
Slide 16: LatAm FX Trends
LatAm FX Trends 0.014 ARS / MXN** 1 ARS = 0.0135 MXN Local Currency expressed in MXN* 0.013 ARS (12.2)% COP 16.0% BRL (1.7)% 1 ARS = 0.0118 MXN UYU (7.2)% CLP (4.7)% 0.012 PEN (2.6)% BOB (39.3)% 0.011 sep/2025 dic/2025 mar/2026 jun/2026 sep/2026 1 *Average Exchange rate Q3-2025 vs. Q3-2026. **Exchan
Slide 17: LatAm
LATAM Q3 ms Revenues +12.2% “arr margin 23.7%
Slide 18: Foreign Exchange Result
Foreign Exchange Result FX result by quarter millions of MXN 150 100 50 41.1 19.8 0 (2.5) (50) (16.7) (17.1) (100) (93.7) (150) (122.7) (200) (250) (249.8) (300) Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Gain / (loss). Part of the comprehensive financing cost; non-cash.
Slide 19: Debt Profile: Q2-2026 vs. Q3-2026 (June 30, 2026)
Debt Profile: Q2-2026 vs. Q3-2026 As of June 30, 2026 Banks Cebur Short-Term Cebur Long-Term IDB IFC 3,229 1,880 850 650 150 150 150 150 75 2026 2027 2028 2029 2030 2031 2032 2033 2034 Maturity profile by year, millions of MXN (principal at face value). Source: Credits & CEBUR detail as of each date
Slide 20: Debt Profile: Q2-2026 vs. Q3-2026 (September 30, 2026)
Debt Profile: Q2-2026 vs. Q3-2026 As of September 30, 2026 Banks Cebur Short-Term Cebur Long-Term IDB IFC 3,352 1,265 965 765 495 265 265 265 190 115 67 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Maturity profile by year, millions of MXN (principal at face value). Source: Credits & CEBUR
Slide 21: Q3 2025 to Q3 2026 quarterly trend
165 129 120 119 107 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Slide 22: Genomma Lab Internacional announces seventeenth dividend payment
GENOMMA LAB INTERNACIONAL ANNOUNCES SEVENTEENTH DIVIDEND PAYMENT Mexico City, September 22, 2026—- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company’), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international p
Slide 23: The leverage ratio has remained consistently stable over the past six years
The leverage ratio has remained consistently stable over the past six years. 1.4x 2020 2021 2022 2023 2024 2025 Q3 2026
Slide 24: Genomma Lab 2026 Investor Day
Slide 25: Slide 25
Slide 26: Q&A
Slide 27: Genomma Lab
Genomma Lab.°® GENOMMA LAB
Genomma Lab Internacional — Q3 2026 Earnings Presentation on 6ix